New center opens in Suzhou New District, China, to bring local cell culture media optimization support for vaccines, advanced therapies, and biotherapeutic drug development

SANTA ANA, California, May 17, 2022: FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced the completion of its Innovation and Collaboration Center in Suzhou New District, China.

Construction of the new Innovation and Collaboration Center began in December 2021 and is now open to facilitate collaboration between experts and customers for the tailored design of upstream cell culture processes that can meet individual biomanufacturing needs. The new facility will provide the local resources and expertise needed to optimize cell culture media and associated workflows to support commercial production of new drugs in China’s rapidly expanding market.

Yutaka Yamaguchi, chairman and chief executive officer, FUJIFILM Irvine Scientific, commented: “We have seen significant investment and growth within China’s biopharmaceutical, vaccine, cell and gene therapy markets, bolstered by the government’s dedication to making more affordable drugs available. Consequently, we have prioritized the completion and opening of FUJIFILM Irvine Scientific’s Collaboration and Innovation Center, allowing us to expand our expertise throughout this rapidly expanding market and provide local assistance for developing customer-tailored cell culture media solutions and workflows to compliment any biomanufacturing needs.”

FUJIFILM Irvine’s new Suzhou center joins its existing network of optimization services offered by facilities across the USA and Japan.